- Home
- SGLY vs CANF Comparison
SGLY vs CANF Comparison
Compare SGLY & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- CANF
- Stock Information
- Founded
- SGLY 2001
- CANF 1994
- Country
- SGLY United States
- CANF Israel
- Employees
- SGLY N/A
- CANF N/A
- Industry
- SGLY
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- CANF Health Care
- Exchange
- SGLY Nasdaq
- CANF Nasdaq
- Market Cap
- SGLY 5.8M
- CANF 14.4M
- IPO Year
- SGLY 2008
- CANF N/A
- Fundamental
- Price
- SGLY $1.55
- CANF $1.48
- Analyst Decision
- SGLY
- CANF Strong Buy
- Analyst Count
- SGLY 0
- CANF 2
- Target Price
- SGLY N/A
- CANF $14.00
- AVG Volume (30 Days)
- SGLY 13.4K
- CANF 1.2M
- Earning Date
- SGLY 11-14-2024
- CANF 12-31-2024
- Dividend Yield
- SGLY N/A
- CANF N/A
- EPS Growth
- SGLY N/A
- CANF N/A
- EPS
- SGLY N/A
- CANF N/A
- Revenue
- SGLY $2,742,157.00
- CANF $667,000.00
- Revenue This Year
- SGLY N/A
- CANF $409.56
- Revenue Next Year
- SGLY N/A
- CANF N/A
- P/E Ratio
- SGLY N/A
- CANF N/A
- Revenue Growth
- SGLY N/A
- CANF N/A
- 52 Week Low
- SGLY $1.27
- CANF $1.29
- 52 Week High
- SGLY $7.65
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SGLY 43.10
- CANF 35.58
- Support Level
- SGLY $1.58
- CANF $1.30
- Resistance Level
- SGLY $1.71
- CANF $1.72
- Average True Range (ATR)
- SGLY 0.09
- CANF 0.18
- MACD
- SGLY -0.00
- CANF -0.01
- Stochastic Oscillator
- SGLY 35.71
- CANF 17.92
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).